Developer behind wearable device for Tourettes syndrome secures $3.2m – Medical Device Network

Neupulse, a UK-based company that is developing a wristband to help manage the symptoms of Tourettes syndrome, has raised $3.2m in seed financing.

The trade name of Neurotherapeutics Limited, Neupulse spun out from the University of Nottingham in 2021 following positive research into managing tics by electrical stimulation.

The company has developed a wearable device that stimulates the median nerve in the wrist. Neupulse says that the prototype can reduce tic frequency and severity.

A Neupulse spokesperson told Medical Device Network the funding will be used to finalise the prototype and start our regulatory applications.

We are currently developing our Clinical Evaluation Plan, which will determine the level of evaluation required.

The company has already touted results from a clinical trial showcasing the devices capability in managing the symptoms of Tourettes. A total of 121 people across the UK tried the device at home for 15 minutes a day over a month.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

Country * UK USA Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Cte d"Ivoire Croatia Cuba Curaao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Runion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Medical Device Network.

Submit and download

Based on participant feedback, the device led to a reduction in tic frequency of more than 25% while undergoing stimulation. Tic severity was reduced by 35% after four weeks, with more than half of people who received stimulation reporting at least a 25% reduction compared to baseline.

Tourettes syndrome is a neurodevelopmental condition. It is characterised by tics involuntary, repetitive movements and vocalisations. The cause of the syndrome is unclear and there is no cure.

Although there are several medications available to patients that can help manage tics, they also contain side effects such as weight gain and sedation which can impact quality of life. Research has been conducted into non-pharmacological treatments such as transcranial stimulation, but results are varied and there are additional challenges around accessibility.

The scientists behind Neupulse stated in the 2023 research paper that the peripheral nervous system presents an alternative stimulation target. Based on previous positive data, which tested electrical stimulation on the median nerve, the team developed a wearable device. Kinneir Dufort, a design consultancy, helped the team build the product.

Neupulse CEO Paul Cable said: Our device is an alternative to the current provision of treatment for Tourettes syndrome, which is centred around medication and cognitive behaviour therapy. The goal is for Neupulse to be available to the Tourettes syndrome community globally in the years ahead.

Median nerve stimulation has also been the target of wearable bands for the treatment of nausea. ReliefBand, for example, has a US Food and Drug Administration-cleared product for post-operative nausea.

A market model by GlobalData estimates the global neuromodulation device market will be worth $11.4bn by 2033, up from $6bn in 2022.

Give your business an edge with our leading industry insights.

Visit link:
Developer behind wearable device for Tourettes syndrome secures $3.2m - Medical Device Network